Essex Property Trust, Inc. vs Roivant Sciences Ltd. Common Shares — how do they compare? Essex Property Trust, Inc. trades at $272.92 (market cap $17.26B), while Roivant Sciences Ltd. Common Shares trades at $34.87 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is the larger of the two by market cap, and Essex Property Trust, Inc. pays a 3.86% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Essex Property Trust, Inc. for 111 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| ESS | ROIV | |
|---|---|---|
Market Cap | $17.26B | $24.72B |
Volume | 454,464 | 6,279,442 |
Sector | Real Estate | Health |
52-Week High | $298.33 | $41.81 |
52-Week Low | $239.61 | $16.04 |
Typical Hold Time | 111 Days | 0 Days |
Enterprise Value | $23.86B | $20.99B |
Dividend Yield | 3.86% | — |
Signals from Pluang's Aura AI — not financial advice
ESS trades at $270.20, up 0.8% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 results beating FFO guidance and raised full-year outlook, though recent earnings show volatility with two misses in the last four quarters. Revenue has grown steadily from $1.6B in 2022 to $1.9B in 2025, while profit margins remain healthy at 35.48%.
The stock presents a compelling opportunity with 18 buy ratings and consensus price target of $303.41 (12.3% upside), supported by strong operational performance and litigation resolution. Key risks include elevated valuation multiples (P/E 41.83) and debt levels, while institutional buying from BlackRock and Canada Pension Plan provides confidence in the recovery thesis.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Essex Property Trust owns a portfolio of 253 apartment communities with over 62,000 units and is developing three additional properties with 571 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
Read more on ESS →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →